Incannex Healthcare Inc. (IXHL)
NASDAQ: IXHL · Real-Time Price · USD
0.3726
+0.0126 (3.50%)
At close: Nov 12, 2025, 4:00 PM EST
0.3729
+0.0003 (0.07%)
After-hours: Nov 12, 2025, 4:06 PM EST
Incannex Healthcare Employees
Incannex Healthcare had 12 employees as of June 30, 2025. The number of employees increased by 3 or 33.33% compared to the previous year.
Employees
12
Change (1Y)
3
Growth (1Y)
33.33%
Revenue / Employee
$7,167
Profits / Employee
-$3,907,083
Market Cap
129.56M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 12 | 3 | 33.33% |
| Jun 30, 2024 | 9 | 6 | 200.00% |
| Jun 30, 2021 | 3 | 1 | 50.00% |
| Jun 30, 2020 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IXHL News
- 13 days ago - Incannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic Focus - GlobeNewsWire
- 21 days ago - Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - GlobeNewsWire
- 2 months ago - Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder - GlobeNewsWire
- 2 months ago - Incannex Healthcare Authorizes $20 Million Share Repurchase Program - GlobeNewsWire
- 3 months ago - Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025 - Update - Newsfile Corp
- 3 months ago - Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea - GlobeNewsWire
- 3 months ago - Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term - GlobeNewsWire
- 3 months ago - Nano-Cap Incannex's Sleep Apnea Candidate Shows Effectiveness And Safety In Mid-Stage Trial - Benzinga